# Mesenchymal Tumor of the Hand Causing Tumor-Induced Osteomalacia

**Authors:** Andrew Cecil, Meti Shagi, Syed Basit Haider, Syed Ali A Gardezi

PMC · DOI: 10.7759/cureus.104071 · Cureus · 2026-02-22

## TL;DR

A rare hand tumor caused bone weakness and low phosphate levels, but was successfully treated with surgery after a long diagnostic journey.

## Contribution

This case highlights the diagnostic challenges and successful treatment of a phosphaturic mesenchymal tumor in an unusual hand location.

## Key findings

- A 55-year-old male with TIO had a mesenchymal tumor in the hand confirmed by imaging and surgery.
- Post-surgery normalization of serum phosphorus confirmed biochemical cure.
- Expert imaging interpretation was crucial for identifying the tumor after initial scans were non-localizing.

## Abstract

Tumor-induced osteomalacia (TIO) is an ultra-rare paraneoplastic syndrome caused by excessive secretion of fibroblast growth factor 23 (FGF23) from phosphaturic mesenchymal tumors, leading to renal phosphate wasting, hypophosphatemia, and osteomalacia. Diagnosis is frequently delayed due to nonspecific symptoms and the difficulty of localizing small, often indolent tumors. We report a 55-year-old male patient who presented with a 16-month history of progressive muscle weakness, chronic bone pain, and multiple bilateral metatarsal fractures. Laboratory evaluation demonstrated profound hypophosphatemia (1.6 mg/dL), markedly elevated FGF23 levels (455 RU/mL), and renal phosphate wasting (tubular reabsorption of phosphate at 35%, tubular maximum phosphate reabsorption per glomerular filtration rate (TmP/GFR) at 1.04 mg/dL). Initial fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) was non-localizing. Following referral to a tertiary center, specialized re-interpretation of imaging identified faint focal uptake in the right third metacarpal. This finding was confirmed with technetium-99m sestamibi scintigraphy and magnetic resonance imaging, which revealed a 1.9 × 1.8 × 1.2 cm soft-tissue mass within the palmar tissues. Surgical excision was performed, and histopathology confirmed a phosphaturic mesenchymal tumor with positive FGF23 in situ hybridization. Postoperatively, serum phosphorus levels normalized, confirming biochemical cure. This case underscores the diagnostic challenges associated with TIO, particularly tumor localization, and highlights the critical role of expert imaging interpretation. Complete surgical resection remains the definitive treatment, resulting in rapid biochemical normalization and clinical improvement. The unusual hand location and initially non-localizing imaging emphasize the importance of a systematic, multidisciplinary approach in the evaluation and management of this rare but highly treatable condition.

## Linked entities

- **Proteins:** FGF23 (fibroblast growth factor 23)
- **Diseases:** Tumor-induced osteomalacia (MONDO:0018124), osteomalacia (MONDO:0001068)

## Full-text entities

- **Genes:** PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, FGF23 (fibroblast growth factor 23) [NCBI Gene 8074] {aka ADHR, FGFN, HFTC2, HPDR2, HYPF, PHPTC}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}
- **Diseases:** reactive airway disease (MESH:D000275), musculoskeletal symptoms (MESH:D009140), Osteomalacia (MESH:D010018), endocrine disorders (MESH:D004700), fourth metatarsal fractures (MESH:D005530), hypophosphatemia (MESH:D017674), defective bone mineralization (MESH:D012080), hypertension (MESH:D006973), paraneoplastic disorder (MESH:D010257), Mesenchymal Tumor (MESH:C535700), renal phosphate wasting (MESH:D019282), sternal pain (MESH:C537489), osteopenia (MESH:D001851), mitral valve prolapse (MESH:D008945), muscle weakness (MESH:D018908), Tumor (MESH:D009369), bone pain (MESH:D010146), fracture (MESH:D050723), hyperlipidemia (MESH:D006949), TIO (MESH:C537751), trauma (MESH:D014947)
- **Chemicals:** 1,25-dihydroxyvitamin D (MESH:C097949), calcitriol (MESH:D002117), burosumab (MESH:C000601956), FDG (MESH:D019788), TmP (MESH:D013938), 25-hydroxy vitamin D (MESH:C104450), 25-OH vitamin D (-), octreotide (MESH:D015282), testosterone (MESH:D013739), Technetium-99m sestamibi (MESH:D017256), potassium phosphate (MESH:C013216), 68Ga-DOTATATE (MESH:C513399), phosphate (MESH:D010710), phosphorus (MESH:D010758), vitamin D (MESH:D014807)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12926697/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12926697/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC12926697/full.md

---
Source: https://tomesphere.com/paper/PMC12926697